Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Characterizing Real-World Use Of Tiotropium In Asthma In The USA.

Averell CM, Laliberté F, Duh MS, Wu JW, Germain G, Faison S.

J Asthma Allergy. 2019 Oct 7;12:309-321. doi: 10.2147/JAA.S216932. eCollection 2019.

2.

Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study.

Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Duh MS, Young JB.

Curr Med Res Opin. 2019 Oct 18:1. doi: 10.1080/03007995.2019.1682981. [Epub ahead of print]

PMID:
31625766
3.

Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs.

Averell CM, Stanford RH, Laliberté F, Wu JW, Germain G, Duh MS.

J Asthma. 2019 Oct 14:1-10. doi: 10.1080/02770903.2019.1663429. [Epub ahead of print]

PMID:
31607180
4.

Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA.

Grivas P, DerSarkissian M, Shenolikar R, Laliberté F, Doleh Y, Duh MS.

Future Oncol. 2019 Oct 9. doi: 10.2217/fon-2019-0434. [Epub ahead of print]

5.

Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.

Huynh L, Cai B, Cheng M, Lax A, Lejeune D, Duh MS, Kim MK.

Pancreas. 2019 Oct;48(9):1126-1135. doi: 10.1097/MPA.0000000000001403.

PMID:
31593022
6.

Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.

Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberté F, Duh MS.

Oncologist. 2019 Oct 7. pii: theoncologist.2019-0240. doi: 10.1634/theoncologist.2019-0240. [Epub ahead of print]

PMID:
31591140
7.

Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.

Bobbili P, Ryan K, Duh MS, Dua A, Fernandes AW, Pavilack M, Gomez JE.

Future Oncol. 2019 Sep 23. doi: 10.2217/fon-2019-0282. [Epub ahead of print]

8.

Adherence to heart failure management medications following cardiac resynchronization therapy.

Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, Duh MS, Dasta JF.

Curr Med Res Opin. 2019 Oct 7:1-9. doi: 10.1080/03007995.2019.1670474. [Epub ahead of print]

PMID:
31535559
9.

Direct and Indirect Cost of Obesity Among the Privately Insured in the United States: A Focus on the Impact by Type of Industry.

Ramasamy A, Laliberté F, Aktavoukian SA, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, Duh MS.

J Occup Environ Med. 2019 Aug 16. doi: 10.1097/JOM.0000000000001693. [Epub ahead of print]

PMID:
31425324
10.

Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations.

Cheng WY, Chang R, Novy P, O'Connor C, Duh MS, Hogea CS.

Hum Vaccin Immunother. 2019 Aug 16:1-13. doi: 10.1080/21645515.2019.1632679. [Epub ahead of print]

PMID:
31419168
11.

Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.

Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D.

BMC Cancer. 2019 Mar 28;19(1):274. doi: 10.1186/s12885-019-5459-x.

12.

The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007-2015.

Ghaswalla PK, Patterson BJ, Cheng WY, Duchesneau E, Macheca M, Duh MS, Trofa AF.

Prev Med Rep. 2019 Feb 18;14:100833. doi: 10.1016/j.pmedr.2019.100833. eCollection 2019 Jun.

13.

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.

Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 19;14:343-352. doi: 10.2147/COPD.S184653. eCollection 2019.

14.

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.

Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R.

Clin Ther. 2019 Mar;41(3):477-493.e7. doi: 10.1016/j.clinthera.2019.01.009. Epub 2019 Feb 14.

PMID:
30773308
15.

Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.

Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

Am J Hematol. 2019 Apr;94(4):E96-E99. doi: 10.1002/ajh.25408. Epub 2019 Jan 31. No abstract available.

16.

Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.

Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH.

Oncologist. 2019 Aug;24(8):1066-1075. doi: 10.1634/theoncologist.2018-0520. Epub 2019 Jan 4.

PMID:
30610008
17.

A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States.

Appukkuttan S, Duchesneau E, Zichlin ML, Bhak RH, Yaldo A, Gharibo M, Babajanyan S, Duh MS.

J Manag Care Spec Pharm. 2019 Jan 4:1-12. doi: 10.18553/jmcp.2019.18259. [Epub ahead of print]

18.

Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.

Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK.

Oncologist. 2019 Aug;24(8):1056-1065. doi: 10.1634/theoncologist.2018-0519. Epub 2019 Jan 3.

PMID:
30606883
19.

An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.

Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M.

J Diabetes Complications. 2019 Feb;33(2):140-147. doi: 10.1016/j.jdiacomp.2018.10.016. Epub 2018 Oct 31.

20.

Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study.

Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D.

Medicine (Baltimore). 2018 Nov;97(47):e13390. doi: 10.1097/MD.0000000000013390.

21.

Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus.

Zonnenberg BA, Neary MP, Duh MS, Ionescu-Ittu R, Fortier J, Vekeman F.

PLoS One. 2018 Nov 15;13(11):e0204646. doi: 10.1371/journal.pone.0204646. eCollection 2018.

22.

Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.

Khelif A, Saleh MN, Salama A, Portella MDSO, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB.

Am J Hematol. 2019 Feb;94(2):200-208. doi: 10.1002/ajh.25348. Epub 2018 Nov 29.

23.

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.

Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Menopause. 2018 Nov;25(11):1297-1305. doi: 10.1097/GME.0000000000001232.

PMID:
30358726
24.

Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.

Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS.

Future Oncol. 2019 Feb;15(4):359-370. doi: 10.2217/fon-2018-0671. Epub 2018 Oct 15.

PMID:
30317881
25.

Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database.

Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 12;13:2859-2868. doi: 10.2147/COPD.S167379. eCollection 2018.

26.

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.

Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS.

Melanoma Res. 2019 Jun;29(3):301-310. doi: 10.1097/CMR.0000000000000504.

27.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.

Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS.

Melanoma Res. 2018 Dec;28(6):618-628. doi: 10.1097/CMR.0000000000000507.

28.

Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.

Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP.

Urol Oncol. 2018 Nov;36(11):500.e1-500.e9. doi: 10.1016/j.urolonc.2018.08.002. Epub 2018 Sep 7.

29.

Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.

Vekeman F, Weiss L, Aram J, Ionescu-Ittu R, Moosavi S, Xiao Y, Cheng WY, Bhak RH, Tawadrous M, Capparella MR, Montravers P, Duh MS.

BMC Infect Dis. 2018 Aug 29;18(1):438. doi: 10.1186/s12879-018-3333-0.

30.

Burden of disease associated with a COPD eosinophilic phenotype.

Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 13;13:2425-2433. doi: 10.2147/COPD.S170995. eCollection 2018.

31.

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.

Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

Cardiovasc Diabetol. 2018 Aug 24;17(1):118. doi: 10.1186/s12933-018-0759-z.

32.

Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data.

Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B.

J Asthma. 2019 Aug;56(8):808-815. doi: 10.1080/02770903.2018.1502301. Epub 2018 Oct 16.

PMID:
30130418
33.

Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.

Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS.

Curr Med Res Opin. 2018 Dec;34(12):2169-2176. doi: 10.1080/03007995.2018.1501351. Epub 2018 Aug 5.

PMID:
30009647
34.

Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.

Kallenbach L, Shui AM, Cheng WY, Fan T, Hu W, Zichlin ML, Duh MS, Ye F, Levin PA.

Endocr Pract. 2018 Sep;24(9):805-814. doi: 10.4158/EP-2017-0261. Epub 2018 Jul 5.

PMID:
29975575
35.

Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis.

Ghaswalla PK, Patterson BJ, Cheng WY, Duchesneau E, Macheca M, Duh MS.

Hum Vaccin Immunother. 2018;14(11):2780-2785. doi: 10.1080/21645515.2018.1489189. Epub 2018 Jul 12.

36.

Removal of ineligible outcome cases reduces confounding.

Walker AM, Schneeweiss S, DerSarkissian M, Duh MS.

Clin Epidemiol. 2018 May 21;10:575-579. doi: 10.2147/CLEP.S160482. eCollection 2018.

37.

Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.

Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

Clin Colorectal Cancer. 2018 Sep;17(3):e531-e539. doi: 10.1016/j.clcc.2018.04.002. Epub 2018 Apr 21.

38.

Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials.

Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, Ziemann A, Isojarvi J.

Epilepsy Res. 2018 Jul;143:120-129. doi: 10.1016/j.eplepsyres.2017.10.004.

39.

Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.

Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M.

Curr Med Res Opin. 2018 Nov;34(11):1959-1966. doi: 10.1080/03007995.2018.1470500. Epub 2018 Jun 4. Erratum in: Curr Med Res Opin. 2019 Mar;35(3):559.

PMID:
29701080
40.

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.

Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):257-265. doi: 10.1016/j.clml.2018.02.010. Epub 2018 Feb 17.

PMID:
29519619
41.

Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.

Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA.

Curr Med Res Opin. 2018 Jun;34(6):1099-1115. doi: 10.1080/03007995.2018.1444591. Epub 2018 Mar 5.

PMID:
29468896
42.

Claims-based risk model for first severe COPD exacerbation.

Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan JFP, Duh MS.

Am J Manag Care. 2018 Feb 1;24(2):e45-e53.

43.

Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center.

Ruud Bosch JLH, Vekeman F, Duh MS, Neary M, Magestro M, Fortier J, Karner P, Ionescu-Ittu R, Zonnenberg BA.

Int Urol Nephrol. 2018 Mar;50(3):459-467. doi: 10.1007/s11255-017-1766-9. Epub 2018 Jan 15.

44.

Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis.

Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G.

Curr Med Res Opin. 2018 Jul;34(7):1261-1269. doi: 10.1080/03007995.2017.1416347. Epub 2018 Jan 10.

PMID:
29231748
45.

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.

Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

Med Oncol. 2017 Nov 4;34(12):193. doi: 10.1007/s12032-017-1049-4.

46.

Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.

Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

Med Oncol. 2017 Aug 10;34(9):160. doi: 10.1007/s12032-017-1014-2.

47.

Public health impact of Rotarix vaccination among commercially insured children in the United States.

Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS.

Vaccine. 2017 Sep 5;35(37):5065-5072. doi: 10.1016/j.vaccine.2017.06.034. Epub 2017 Aug 1.

48.

Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.

Faught E, Laliberté F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, Duh MS.

Epilepsia. 2017 Oct;58(10):1742-1748. doi: 10.1111/epi.13857. Epub 2017 Jul 25.

49.

Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.

Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

Clin Genitourin Cancer. 2017 Jun 19. pii: S1558-7673(17)30170-2. doi: 10.1016/j.clgc.2017.06.004. [Epub ahead of print]

PMID:
28729067
50.

A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.

Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 21;12:1825-1836. doi: 10.2147/COPD.S129007. eCollection 2017.

Supplemental Content

Support Center